Bliss GVS Pharma Ltd Stock Price Today (NSE: BLISSGVS)
Fundamental Score
Bliss GVS Pharma Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
Bliss GVS Pharma Ltd share price today is ₹231.20, up +0.00% on NSE/BSE as of 17 February 2026. Bliss GVS Pharma Ltd (BLISSGVS) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹1.64K (Cr). The 52-week high for BLISSGVS share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 15.00x, BLISSGVS is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 8.36% and a debt-to-equity ratio of 0.05.
Bliss GVS Pharma Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Bliss GVS Pharma Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Bliss GVS Pharma Share Price: A Financial Stability Analysis
The pharmaceutical sector is currently navigating a complex landscape, with increased scrutiny on pricing and supply chain resilience. Evaluating the financial health of individual companies is crucial in this environment. This analysis examines the financial stability of Bliss GVS Pharma, focusing on its current metrics. The current Bliss GVS Pharma share price stands at ₹183.1999969482422, with a Price-to-Earnings (PE) ratio of 15.0 and a Return on Capital Employed (ROCE) of 11.72%. This prompts a need to understand how these figures play into Bliss GVS Pharma's overall financial position and its relative performance against sector peers like
Mankind Pharma Ltd.The PE ratio of 15.0 suggests the market is valuing Bliss GVS Pharma at 15 times its earnings. It's vital to compare this to the sector average and peers like Mankind Pharma Ltd, Smruthi Organics Ltd, and Balaxi Pharmaceuticals Ltd to gauge whether the company is undervalued, overvalued, or fairly priced. While a lower PE compared to the industry average might suggest undervaluation, it's essential to also consider the overall quality of management. For instance, contrasting the experience of the management team with a peer like
Mankind Pharma Ltd and their proven track record of revenue generation in a similar environment, can provide insights into the premium that may be placed upon the shares of their competitors.The ROCE of 11.72% is a key indicator of how effectively Bliss GVS Pharma is using its capital to generate profits. While a healthy ROCE generally signifies efficient capital allocation, it's imperative to analyze the sustainability of this return. The magnitude of this ROCE impacts Bliss GVS Pharma's moat (competitive advantage). A consistently high ROCE would indicate a robust moat, suggesting the company can defend its market share and profitability from competitors. However, a lower ROCE compared to competitors signals a thinner moat. This also raises concerns about the firm's ability to fend off competition or reinvest in innovation and growth.
This analysis is a component of a broader, 80-parameter fundamental audit of Bliss GVS Pharma Ltd. The audit is overseen and verified by Sweta Mishra, ensuring a comprehensive evaluation. The observations presented here are not intended as financial advice, and should not be used to formulate investment decisions. The intent is only to provide an overview of the current financial stability situation.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Bliss GVS Pharma Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of BLISSGVS across key market metrics for learning purposes.
Positive Indicators
6 factors identified
Strong Operating Margins (16.95%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Attractive Valuation (P/E: 15.00 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Conservative Debt Levels (D/E: 0.05)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (15.52x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹167.14 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
4 factors identified
Below-Average Return on Equity (8.36%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Limited Growth History (3.27% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Earnings Growth (-4.93% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-4.53% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Bliss GVS Pharma Ltd Financial Statements
Comprehensive financial data for Bliss GVS Pharma Ltd including income statement, balance sheet and cash flow
About BLISSGVS (Bliss GVS Pharma Ltd)
Bliss GVS Pharma Ltd (BLISSGVS) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current market capitalisation of ₹1.64K (Cr). Bliss GVS Pharma Ltd has delivered a Return on Equity (ROE) of 8.36% and a ROCE of 11.72%. The debt-to-equity ratio stands at 0.05, reflecting the company's capital structure. Investors tracking BLISSGVS share price can monitor key metrics including P/E ratio, promoter holding of 35.39%, and quarterly earnings growth.
Company Details
Key Leadership
Corporate Events
BLISSGVS Share Price: Frequently Asked Questions
What is the current share price of Bliss GVS Pharma Ltd (BLISSGVS)?
As of 17 Feb 2026, 10:08 am IST, Bliss GVS Pharma Ltd share price is ₹231.20. The BLISSGVS stock has a market capitalisation of ₹1.64K (Cr) on NSE/BSE.
Is BLISSGVS share price Overvalued or Undervalued?
BLISSGVS share price is currently trading at a P/E ratio of 15.00x, compared to the industry average of 31.77x. Based on this relative valuation, the Bliss GVS Pharma Ltd stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of BLISSGVS share price?
The 52-week high of BLISSGVS share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Bliss GVS Pharma Ltd share price?
Key factors influencing BLISSGVS share price include quarterly earnings growth (Sales Growth: 12.27%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Bliss GVS Pharma Ltd a good stock for long-term investment?
Bliss GVS Pharma Ltd shows a 5-year Profit Growth of -4.53% and an ROE of 8.36%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.05 before investing in BLISSGVS shares.
How does Bliss GVS Pharma Ltd compare with its industry peers?
Bliss GVS Pharma Ltd competes with major peers in the Pharmaceuticals. Investors should compare BLISSGVS share price P/E of 15.00x and ROE of 8.36% against the industry averages to determine competitive standing.
What is the P/E ratio of BLISSGVS and what does it mean?
BLISSGVS share price has a P/E ratio of 15.00x compared to the industry average of 31.77x. Investors pay ₹15 for every ₹1 of annual earnings.
How is BLISSGVS performing according to Bull Run's analysis?
BLISSGVS has a Bull Run fundamental score of 34/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does BLISSGVS belong to?
BLISSGVS operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Bliss GVS Pharma Ltd share price.
What is Return on Equity (ROE) and why is it important for BLISSGVS?
BLISSGVS has an ROE of 8.36%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Bliss GVS Pharma Ltd generates profits from shareholders capital.
How is BLISSGVS debt-to-equity ratio and what does it indicate?
BLISSGVS has a debt-to-equity ratio of 0.05, which indicates conservative financing with low financial risk.
What is BLISSGVS dividend yield and is it a good dividend stock?
BLISSGVS offers a dividend yield of 0.32%, meaning you receive ₹0.32 annual dividend for every ₹100 invested in Bliss GVS Pharma Ltd shares.
How has BLISSGVS share price grown over the past 5 years?
BLISSGVS has achieved 5-year growth rates of: Sales Growth 3.27%, Profit Growth -4.53%, and EPS Growth -4.93%.
What is the promoter holding in BLISSGVS and why does it matter?
Promoters hold 35.39% of BLISSGVS shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Bliss GVS Pharma Ltd.
What is BLISSGVS market capitalisation category?
BLISSGVS has a market capitalisation of ₹1644 crores, placing it in the Small-cap category.
How volatile is BLISSGVS stock?
BLISSGVS has a beta of N/A. A beta > 1 suggests the Bliss GVS Pharma Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is BLISSGVS operating profit margin trend?
BLISSGVS has a 5-year average Operating Profit Margin (OPM) of 16.95%, indicating the company's operational efficiency.
How is BLISSGVS quarterly performance?
Recent quarterly performance shows Bliss GVS Pharma Ltd YoY Sales Growth of 12.27% and YoY Profit Growth of 12.32%.
What is the institutional holding pattern in BLISSGVS?
BLISSGVS has FII holding of 13.27% and DII holding of 5.98%. Significant institutional holding often suggests professional confidence in the Bliss GVS Pharma Ltd stock.